Human immunodeficiency virus and infertility

Saxena, Pinkee; Ghumman, Surveen

doi:10.4103/2394-4285.288713

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, MAR, such as IUI or IVF/ICSI, may be needed to treat infertility in people living with HIV. HIV status may decrease fertility and/or MAR outcomes, particularly in women, although more research is needed on this issue [8][9][10][11][12][13]. In cis-women (hereafter referred to as women/females), this may be related to higher incidence of pelvic inflammatory diseases and tubal diseases, and the potential effect of HIV status on the endocrine system.…”

Section: Introductionmentioning

confidence: 99%

Medically assisted reproduction for people living with HIV in Europe: A cross‐country exploratory policy comparison

et al. 2022

View full text Add to dashboard Cite

Objective: To explore the availability and accessibility of medically assisted reproduction (MAR) for people living with HIV in Europe, including the feasibility of cross-border care. Methods:We used a polymorphous engagement approach, primarily based on digital and email-based interviews with representatives of national HIV organizations, clinical researchers (infectious disease and/or infertility specialists), European and national professional societies (fertility and/or infectious disease), national regulatory authorities and individual clinics in 14 countries in the WHO European region. The research design and results were also informed by two surveys and a review of the secondary literature, news articles and clinic websites. Results:Although MAR is possible for people living with HIV in 12 out of the 14 countries mapped, accessing services can be challenging for logistical or financial reasons. People living with HIV also face barriers to MAR independent of their HIV status, such as limitations on single women and same-sex couples accessing services. Cross-border care is available for most patients who are self-financing but is limited for publicly funded patients. Conclusions:Even when MAR is available to and accessible for people living with HIV, there may still be barriers to treatment. Further research on patient experiences is needed to understand these discrepancies between availability and accessibility on paper and in practice.

show abstract